Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02063724 · ClinicalTrials.gov registry record · Phase 1
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02063724 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 15 participants.
The verdict
NCT02063724, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and immunogenicity of HER-2 pulsed DC1 vaccine in high risk HER-2 high and intermediate expression breast cancers. Participants will have HER-2 driven IBC at least Stage IIIA with N2 following chemotherapy with/without trastuzumab or recurrence exclusive of new primary tumor but rendered NED. Mammogram, laboratory studies, CT, and leukapheresis will be performed, in addition to vaccine administration.
Interventions
- BIOLOGICAL HER-2 pulsed Dendritic Cell Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-10-01 |
| Est. Completion | 2022-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02063724
The ClinicalTrials.gov registry entry for NCT02063724 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HER-2 pulsed Dendritic Cell Vaccine is the first listed.
NCT02063724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02063724 about?
NCT02063724 is a clinical study titled "HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer". The purpose of this study is to determine the safety and immunogenicity of HER-2 pulsed DC1 vaccine in high risk HER-2 high and intermediate expression breast cancers. Participants will have HER-2 driven IBC at least Stage IIIA with N2 following chemotherapy with/without trastuzumab or recurrence ex...
What is the current status of trial NCT02063724?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-10-01. Estimated completion is 2022-09.
What interventions are being tested in trial NCT02063724?
The interventions under investigation include: HER-2 pulsed Dendritic Cell Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02063724?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.